Core Viewpoint - Xilio Therapeutics, Inc. has successfully closed a public offering of pre-funded warrants and common stock warrants, raising approximately $50 million, with potential total gross proceeds of up to $150 million by the end of 2026 if all warrants are exercised for cash [1][5]. Group 1: Offering Details - The offering included pre-funded warrants to purchase 66,676,000 shares of common stock, along with Series A, B, and C warrants, all sold together at a combined public offering price of $0.7499 [2][4]. - The Series B warrants are exercisable at $0.75 per share between November 1, 2025, and December 2, 2025, potentially generating an additional $50 million if fully exercised [4]. - The Series C warrants are also exercisable at $0.75 per share between June 1, 2026, and December 2, 2026, with the same potential additional proceeds of $50 million if fully exercised [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Xilio's product candidates and for working capital and general corporate purposes [5]. Group 3: Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [8].

Core Viewpoint - Xilio Therapeutics, Inc. has announced a public offering of pre-funded warrants and various series of warrants to raise approximately $50 million, aimed at advancing its tumor-activated immuno-oncology therapies for cancer treatment [1][3][4]. Group 1: Offering Details - The public offering includes 66,676,000 pre-funded warrants and corresponding Series A, B, and C warrants, with a combined offering price of $0.7499 per unit [1]. - The offering is expected to close around June 5, 2025, pending customary closing conditions [1]. - The initial gross proceeds from the offering are projected to be approximately $50 million before deducting underwriting discounts and commissions [3]. Group 2: Warrant Specifications - Pre-funded warrants are immediately exercisable until fully exercised, while Series A warrants can be exercised starting December 1, 2025, with an exercise price of $0.75 per share [2]. - Series B warrants will be exercisable on or after November 1, 2025, and Series C warrants on or after June 1, 2026, both with an exercise price of $0.75 per share [2]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of product candidates and for working capital and general corporate purposes [4]. Group 4: Company Overview - Xilio Therapeutics is focused on developing tumor-activated immuno-oncology therapies designed to improve cancer treatment outcomes while minimizing systemic side effects [8].

Core Viewpoint - Xilio Therapeutics, Inc. is initiating an underwritten public offering of pre-funded warrants and various series of warrants to purchase shares of common stock, aimed at advancing its product candidates and supporting general corporate needs [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants and Series A, B, and C warrants for purchasing common stock, all offered by Xilio [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the specific terms [1]. - Leerink Partners is acting as the sole bookrunner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to further develop product candidates and for working capital and other corporate purposes [2]. Group 3: Regulatory Information - A shelf registration statement related to the securities was filed with the SEC on March 11, 2025, and was declared effective on May 8, 2025 [3]. - The offering will be conducted through a prospectus supplement and accompanying prospectus, which will be available on the SEC's website [3]. Group 4: Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes while minimizing systemic side effects [5]. - The company is leveraging a proprietary platform to advance a pipeline of novel, tumor-activated immuno-oncology molecules [5].

WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.755 per share, ...